Phase 2 trial results of lixisenatide published
The full results of the one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide have now been published. This Cure Parkinson’s co-funded trial has reported positive results, indicating that the treatment may slow the progression of motor symptoms. Researchers have reported that the...
Learn more
Fundraiser of the Year Award 2023
We are thrilled to announce that we have two winners of our 2023 Fundraiser of the Year Award: Antony Rose and Michelle Gillies! These two incredible supporters went ‘above and beyond’ to support our vital research by spending 2023 raising funds and awareness in their…
Phase 2 trial results of lixisenatide published
The full results of the one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide have now been published. This Cure Parkinson’s co-funded trial has reported positive results, indicating that the treatment may slow the progression of motor symptoms. Researchers have reported that the…
Upcoming GBA1 conference in Montreal
Cure Parkinson’s is co-sponsoring a large three-day international conference on June 27th – 29th that will be focused on all aspects of GBA1 research, from basic science to clinical trials.
Time to ROCK-PD
Researchers in Germany are conducting a new phase 2 clinical trial to determine if an existing cardiovascular drug called fasudil, could help people with Parkinson’s.
The Movers & Shakers ‘Parky Charter’ petition
We are supporting the Movers & Shakers, along with Parkinson’s UK and Spotlight YOPD, to call on the government to take action to improve the lives of people with Parkinson’s. The Movers & Shakers headed to Downing Street on World Parkinson’s Day (11 April) to…